Reports by Industry
Reports by Company
- Company Analysis(173)
- Company Profile(60)
Global T-Cell Immunotherapy Market for Cancer & Pipeline Analysis
Format : 
Adobe Reader (PDF) Upto 24 hour delivery
Publish Date : Aug, 2018| No. of Pages : 110
Please make your selection :
Electronic Access - Single User License
US$ 1800.00
CD-ROM Mail Delivery
US$ 1900.00
Hard Copy Mail Delivery
US$ 1900.00
Electronic Access - Multi-User License
US$ 2500.00
1. Analyst View
2. Research Methodology
3. Introduction
4. Global T-Cell Immunotherapy Market for Cancer
5. Global CAR T-Cell Immunotherapy Market for Cancer
6. Commercialized CAR T-Cell Immunotherapies for Cancer
6.1 Kymriah
6.2 Yescarta
7. Major Therapeutic Areas for T-Cell Immunotherapies
7.1 Hematological Malignancies
7.1.1 Leukemia
7.1.2 Lymphoma
7.1.3 Multiple Myeloma
7.2 Solid Tumors
7.2.1 Melanoma
7.2.2 Bladder Cancer
7.2.3 Kidney Cancer
7.2.4 Ovarian Cancer
7.2.5 Breast Cancer
7.2.6 Lung Cancer
8. T-Cell Immunotherapy Pipeline Analysis
8.1 By Industry
8.1.1 By Vector
8.1.2 By Clinical Trial Phase
8.1.3 By Indication
8.1.4 By Technology
8.1.5 By Key Players
8.1.6 By Geography
8.2 By Research Collaborations
9. Market Opportunities
10. Key Player Analysis
10.1 Adaptimmune Therapeutics plc
10.2 Juno Therapeutics, Inc.
10.3 Gilead Sciences, Inc.
10.4 Novartis International AG
10.5 Tessa Therapeutics Pte Ltd.
10.6 Gradalis, Inc.
10.7 Immunovative Therapies, Ltd.
10.8 Iovance Biotherapeutics, Inc. (Formerly Lion Biotechnologies, Inc.)
10.9 Atara Biotherapeutics, Inc.
10.10 Celgene Corporation
10.11 Cellular Biomedicine Group
10.12 GlaxoSmithKline plc.
10.13 Immunocore Ltd.
10.14 Inovio Pharmaceuticals, Inc.
10.15 Cell Medica
Not able to find data you are looking for? Ask our Research Analyst.
media citation
- testtest
19 Jan, 2024 - Yourstory.com News @ Foodtech startup Swiggy launches Health Hub in Chennai
23 Mar, 2021 - Yourstory.com News @ Zomato forays into dietary supplements, makes its own 'made in India' brand
16 Mar, 2021 - View more
get in touch
Copyright © 2018, RNCOS, 2002-2018
About Us
Terms & Policy
Contact